ASH 2017 | Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib

Constantine Tam

Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of efficacy and safety as the current PD-1 inhibitors pembrolizumab and nivolumab, as explained here by Constantine Tam, MD, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, Melbourne, Australia. However, the main area of interest in this drug would be to see its efficacy when combined with a BTK inhibitor, which is currently happening in a Phase Ib study (NCT02795182). This interview was recorded at the American Society of Hematology (ASH) Annual Meeting 2017, held in Atlanta, GA.

Share this video  
Similar topics
Related videos
2:17
Opinion: value of MRD as an endpoint in hem-onc clinical trials
Robert Hills
2:24
Judging the value of a clinical trial in hem-onc
Robert Hills
1:20
Investigating vaccines for hem-onc: key questions
David Avigan
2:03
The challenging field of hem-onc therapeutics
Steven Rosen
1:22
Update on CAR T-cell therapy at the City of Hope
Steven Rosen
B-Cell Lymphoma, General
Antibodies, BGB-3111, BGB-A317, Checkpoint Inhibitors, Nivolumab, Pembrolizumab, Tislelizumab, Zanubrutinib
ASH 2017
Interview
9th December 2017
More from Constantine Tam
A novel BTK inhibitor BGB-3111: new data presented at ASH 2017
First results from Bgb-3111 in CLL and Waldenström’s macroglobulinemia
Cessation of venetoclax and remaining in remission from CLL?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals